Torrent Pharma Q4 Revenue Soars 42% to ₹4,197 Cr After JB Pharma Buy

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorVihaan Mehta|Published at:
Torrent Pharma Q4 Revenue Soars 42% to ₹4,197 Cr After JB Pharma Buy
Overview

Torrent Pharmaceuticals reported a strong Q4 FY25-26, with consolidated revenue jumping 42% to ₹4,197 crores and operating EBITDA rising 41% to ₹1,356 crores. The significant growth was primarily driven by the acquisition of JB Pharma.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Torrent Pharma Reports Strong Q4 FY25-26 Results

Torrent Pharmaceuticals announced robust financial results for the fourth quarter of FY25-26. Consolidated revenue surged 42% year-on-year to ₹4,197 crores. Consolidated Operating EBITDA also saw a significant increase of 41%, reaching ₹1,356 crores and maintaining a healthy margin of 32.3%.

Acquisition Drives Growth

The impressive revenue increase was largely due to the consolidation of JB Pharma, following Torrent Pharma's acquisition of a controlling stake. This strategic move, effective January 21, 2026, has quickly demonstrated its financial impact by integrating JB Pharma's performance into Torrent Pharma's overall results.

Base Business Performance

Beyond the acquisition impact, Torrent Pharma's core business also showed resilience. The company reported a 16% revenue growth from its existing operations, with operating EBITDA margins at 32.7% for the quarter.

Supply Chain Setback in Germany

Despite the overall strong performance, the company faced a setback in the German market. Supply disruptions originating from a third-party supplier impacted performance in the region, although this is noted as a minor concern.

Dividend and Future Plans

Torrent Pharma's board proposed a final dividend of ₹9 per equity share. Investors will be closely monitoring the progress of the amalgamation scheme for JB Pharma into Torrent Pharma, which has been filed with the NCLT. The company will also assess the effect of new labor codes expected to be implemented from November 21, 2025.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.